Trials / Completed
CompletedNCT02622243
Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge
Duration of Bronchoprotection of the Long Acting Muscarinic Antagonists Tiotropium and Glycopyrronium Against Methacholine Induced Bronchoconstriction
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 13 (actual)
- Sponsor
- University of Saskatchewan · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The study will assess the duration of protection of single doses of 2 different long acting muscarinic antagonists against methacholine induced bronchoconstriction.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tiotropium | long acting muscarinic antagonist |
| DRUG | glycopyrronium | long acting muscarinic antagonist |
| DEVICE | Respimat | inhaler device used to deliver active tiotropium or placebo |
| DEVICE | Breezehaler | inhaler device used to deliver active glycopyrronium or placebo |
Timeline
- Start date
- 2015-11-01
- Primary completion
- 2016-03-01
- Completion
- 2016-03-01
- First posted
- 2015-12-04
- Last updated
- 2016-04-20
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT02622243. Inclusion in this directory is not an endorsement.